AAAAAA

   
Results: 1-25 | 26-50 | 51-58
Results: 1-25/58
LUNG FIBROSIS INDUCED BY PACLITAXEL
Authors: SOTIRIOU C VANHOUTTE P KLASTERSKY J
Citation: C. Sotiriou et al., LUNG FIBROSIS INDUCED BY PACLITAXEL, Supportive care in cancer, 6(1), 1998, pp. 68-71
A PHASE-III RANDOMIZED STUDY COMPARING, IN NON METASTATIC UNRESECTABLE NONSMALL CELL LUNG-CANCER (NSCLC) RESPONDING TO CHEMOTHERAPY (CT), FURTHER CT TO LOCO-REGIONAL IRRADIATION (RT)
Authors: SCULIER JP PAESMANS M BUREAU G RECLOUX P BAUMOHL J VANCUTSEM O BERCHIER MC THIRIAUX J LAFITTE JJ MOMMEN P VANHOUTTE P NINANE V KLASTERSKY J
Citation: Jp. Sculier et al., A PHASE-III RANDOMIZED STUDY COMPARING, IN NON METASTATIC UNRESECTABLE NONSMALL CELL LUNG-CANCER (NSCLC) RESPONDING TO CHEMOTHERAPY (CT), FURTHER CT TO LOCO-REGIONAL IRRADIATION (RT), Annals of oncology, 9, 1998, pp. 399-399
IS CHEMOSENSITIVITY A PREDICTIVE FACTOR FOR RADIOSENSITIVITY IN NONSMALL CELL LUNG-CANCER - LESSON FROM EUROPEAN LUNG-CANCER WORKING PARTY PHASE-III RANDOMIZED TRAIL
Authors: BAUMOHL J SCULIER JP PAESMANS M BUREAU G RECLOUX P VANCUTSEM O BERCHIER MC THIRIAUX J LAFITTE JJ MOMMEN P VANHOUTTE P NINANE V KLASTERSKY J
Citation: J. Baumohl et al., IS CHEMOSENSITIVITY A PREDICTIVE FACTOR FOR RADIOSENSITIVITY IN NONSMALL CELL LUNG-CANCER - LESSON FROM EUROPEAN LUNG-CANCER WORKING PARTY PHASE-III RANDOMIZED TRAIL, Annals of oncology, 9, 1998, pp. 402-402
A PREDICTION MODEL TO IDENTITY CANCER-PATIENTS (PTS) WITH FEBRILE NEUTROPENIA (FN) AT LOW-RISK TO DEVELOP A SERIOUS MEDICAL COMPLICATION - RESULTS FROM A MULTINATIONAL SURVEY CONDUCTED BY THE INFECTION STUDY SECTION OF THE MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER (MASCC)
Authors: KLASTERSKY J
Citation: J. Klastersky, A PREDICTION MODEL TO IDENTITY CANCER-PATIENTS (PTS) WITH FEBRILE NEUTROPENIA (FN) AT LOW-RISK TO DEVELOP A SERIOUS MEDICAL COMPLICATION - RESULTS FROM A MULTINATIONAL SURVEY CONDUCTED BY THE INFECTION STUDY SECTION OF THE MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER (MASCC), Annals of oncology, 9, 1998, pp. 674-674
THE INFECTIOUS COMPLICATIONS OF BRONCHIAL-CANCER
Authors: KLASTERSKY J
Citation: J. Klastersky, THE INFECTIOUS COMPLICATIONS OF BRONCHIAL-CANCER, Revue des maladies respiratoires, 15(4), 1998, pp. 451-459
PHASE-III RANDOMIZED TRIAL COMPARING CISPLATIN AND CARBOPLATIN WITH OR WITHOUT IFOSFAMIDE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER
Authors: SCULIER JP PAESMANS M THIRIAUX J LECOMTE J BUREAU G GINER V EFREMIDIS A LAFITTE JJ BERCHIER MC ALEXOPOULOS CG ZACHARIAS C MOMMEN P NINANE V KLASTERSKY J
Citation: Jp. Sculier et al., PHASE-III RANDOMIZED TRIAL COMPARING CISPLATIN AND CARBOPLATIN WITH OR WITHOUT IFOSFAMIDE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER, Journal of clinical oncology, 16(4), 1998, pp. 1388-1396
SCIENCE AND PRAGMATISM IN THE TREATMENT AND PREVENTION OF NEUTROPENICINFECTION
Authors: KLASTERSKY J
Citation: J. Klastersky, SCIENCE AND PRAGMATISM IN THE TREATMENT AND PREVENTION OF NEUTROPENICINFECTION, Journal of antimicrobial chemotherapy, 41, 1998, pp. 13-24
THE VALUE OF LUNG-FUNCTION MEASUREMENTS FOR THE ASSESSMENT OF CHEMOTHERAPY IN LUNG-CANCER PATIENTS
Authors: PINSON P KLASTERSKY J
Citation: P. Pinson et J. Klastersky, THE VALUE OF LUNG-FUNCTION MEASUREMENTS FOR THE ASSESSMENT OF CHEMOTHERAPY IN LUNG-CANCER PATIENTS, Lung cancer, 19(3), 1998, pp. 179-184
HOW FAR SHOULD WE GO IN TREATING CANCER-PATIENTS
Authors: KLASTERSKY J
Citation: J. Klastersky, HOW FAR SHOULD WE GO IN TREATING CANCER-PATIENTS, European journal of cancer, 33, 1997, pp. 1006-1006
RESPONSE TO CHEMOTHERAPY HAS PREDICTIVE VALUE FOR FURTHER SURVIVAL OFPATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER - 10 YEARS EXPERIENCE OF THE EUROPEAN LUNG-CANCER WORKING PARTY
Authors: PAESMANS M SCULIER JP LIBERT P BUREAU G DABOUIS G THIRIAUX J MICHEL J VANCUTSEM O SERGYSELS R MOMMEN P KLASTERSKY J
Citation: M. Paesmans et al., RESPONSE TO CHEMOTHERAPY HAS PREDICTIVE VALUE FOR FURTHER SURVIVAL OFPATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER - 10 YEARS EXPERIENCE OF THE EUROPEAN LUNG-CANCER WORKING PARTY, European journal of cancer, 33(14), 1997, pp. 2326-2332
TREATMENT OF NEUTROPENIC INFECTION - TRENDS TOWARDS MONOTHERAPY
Authors: KLASTERSKY J
Citation: J. Klastersky, TREATMENT OF NEUTROPENIC INFECTION - TRENDS TOWARDS MONOTHERAPY, Supportive care in cancer, 5(5), 1997, pp. 365-370
THE PROGNOSTIC FACTORS FOR ADVANCED NONSM ALL CELL LUNG-CANCER - THE EXPERIENCE OF THE EUROPEAN LUNG-CANCER WORKING PARTY
Authors: SCULIER JP PAESMANS M LIBERT P BUREAU G DABOUIS G THIRIAUX J MICHEL J VANCUTSEM O SCHMERBER J GINER V BERCHIER MC MOMMEN P SERGYSELS R KLASTERSKY J
Citation: Jp. Sculier et al., THE PROGNOSTIC FACTORS FOR ADVANCED NONSM ALL CELL LUNG-CANCER - THE EXPERIENCE OF THE EUROPEAN LUNG-CANCER WORKING PARTY, Revue des maladies respiratoires, 14(6), 1997, pp. 445-449
CONCURRENT TREATMENTS AND INDUCTION TREATMENTS FOR UNRESECTABLE TUMORS
Authors: KLASTERSKY J CULLEN M SAUSE B BALL D DARWISH S DOUILLARD J KOMAKI R MATTSON K MIRIMANOFF R REBOUL F SAUNDERS M SUTEDJA T EVERETT EV
Citation: J. Klastersky et al., CONCURRENT TREATMENTS AND INDUCTION TREATMENTS FOR UNRESECTABLE TUMORS, Lung cancer, 17, 1997, pp. 27-28
INITIAL EMPIRICAL ANTIBIOTIC-THERAPY FOR NEUTROPENIC FEVER - ANALYSISOF THE CAUSES OF DEATH
Authors: ROSSI C KLASTERSKY J
Citation: C. Rossi et J. Klastersky, INITIAL EMPIRICAL ANTIBIOTIC-THERAPY FOR NEUTROPENIC FEVER - ANALYSISOF THE CAUSES OF DEATH, Supportive care in cancer, 4(3), 1996, pp. 207-212
IN-VITRO ACTIVITY OF TROVAFLOXACIN (CP-99,219), SPARFLOXACIN, CIPROFLOXACIN, AND FLEROXACIN AGAINST RESPIRATORY PATHOGENS
Authors: CROKAERT F AOUN M DUCHATEAU V GRENIER P VANDERMIES A KLASTERSKY J
Citation: F. Crokaert et al., IN-VITRO ACTIVITY OF TROVAFLOXACIN (CP-99,219), SPARFLOXACIN, CIPROFLOXACIN, AND FLEROXACIN AGAINST RESPIRATORY PATHOGENS, European journal of clinical microbiology & infectious diseases, 15(8), 1996, pp. 696-698
RANDOMIZED TRIAL COMPARING INDUCTION CHEMOTHERAPY VERSUS INDUCTION CHEMOTHERAPY FOLLOWED BY MAINTENANCE CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER
Authors: SCULIER JP PAESMANS M BUREAU G GINER V LECOMTE J MICHEL J BERCHIER MC VANCUTSEM O KUSTNER U KROLL F SERGYSELS R MOMMEN P KLASTERSKY J
Citation: Jp. Sculier et al., RANDOMIZED TRIAL COMPARING INDUCTION CHEMOTHERAPY VERSUS INDUCTION CHEMOTHERAPY FOLLOWED BY MAINTENANCE CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER, Journal of clinical oncology, 14(8), 1996, pp. 2337-2344
PROGNOSTIC FACTORS FOR RESPONSE TO CHEMOTHERAPY CONTAINING PLATINUM DERIVATIVES IN PATIENTS WITH UNRESECTABLE NONSMALL CELL LUNG-CANCER (NSCLC)
Authors: BORGES M SCULIER JP PAESMANS M RICHEZ M BUREAU G DABOUIS G LECOMTE J MICHEL J VANCUTSEM O SCHMERBER J GINER V BERCHIER MC SERGYSELS R MOMMEN P KLASTERSKY J
Citation: M. Borges et al., PROGNOSTIC FACTORS FOR RESPONSE TO CHEMOTHERAPY CONTAINING PLATINUM DERIVATIVES IN PATIENTS WITH UNRESECTABLE NONSMALL CELL LUNG-CANCER (NSCLC), Lung cancer, 16(1), 1996, pp. 21-33
MONOTHERAPY WITH MEROPENEM VERSUS COMBINATION THERAPY WITH CEFTAZIDIME PLUS AMIKACIN AS EMPIRIC THERAPY FOR FEVER IN GRANULOCYTOPENIC PATIENTS WITH CANCER
Authors: COMETTA AF CALANDRA T GAYA H ZINNER SH DEBOCK R DELFAVERO A BUCANEVE G CROKAERT F KERN WV KLASTERSKY J LANGENAEKEN J MICOZZI A PADMOS A PAESMANS M VISCOLI C GLAUSER MP MARTINO P CABALLERO D ENGELHARD D SHAPIRO M CASTAGNOLA E MASSIMO L GIACCHINO R SANZ M GIGIUM M CAROTENUTO M LOPEZ A ANDRIEN JM PAULUS R MARTINO B NOBILE F TOGNI P FERSTER A CUDILLO L LEGRAND JC DINOTA A CAJOZZO A QUINTINI G MARTINEZDALMAU A NOSARI A BUCANEVE GP COMETTA A GALAZZO M GIDDEY M BILLE J BLASER J
Citation: Af. Cometta et al., MONOTHERAPY WITH MEROPENEM VERSUS COMBINATION THERAPY WITH CEFTAZIDIME PLUS AMIKACIN AS EMPIRIC THERAPY FOR FEVER IN GRANULOCYTOPENIC PATIENTS WITH CANCER, Antimicrobial agents and chemotherapy, 40(5), 1996, pp. 1108-1115
A PHASE-II STUDY TESTING A COMBINATION CHEMOTHERAPY WITH EPIRUBICIN AND VINDESINE AS 2ND LINE TREATMENT FOR PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER
Authors: SCULIER JP BUREAU G THIRIAUX J LECOMTE J RECLOUX P BERCHIER MC KROLL F BROHEE D MOMMEN P PAESMANS M SERGYSELS R KLASTERSKY J
Citation: Jp. Sculier et al., A PHASE-II STUDY TESTING A COMBINATION CHEMOTHERAPY WITH EPIRUBICIN AND VINDESINE AS 2ND LINE TREATMENT FOR PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER, International journal of oncology, 7(5), 1995, pp. 1175-1178
A PHASE-II STUDY TESTING WEEKLY PLATINUM DERIVATIVE COMBINATION CHEMOTHERAPY AS 2ND-LINE TREATMENT IN PATIENTS WITH ADVANCED SMALL-CELL LUNG-CANCER
Authors: SCULIER JP THIRIAUX J BUREAU G LAFITTE JJ RECLOUX P BROHEE D BERCHIER MC SERGYSELS R MOMMEN P PAESMANS M KLASTERSKY J LECOMTE J VANSCHAARDENBURG C RICHARD V DIANA D FORTIN F TAGNON A KUSTNER U
Citation: Jp. Sculier et al., A PHASE-II STUDY TESTING WEEKLY PLATINUM DERIVATIVE COMBINATION CHEMOTHERAPY AS 2ND-LINE TREATMENT IN PATIENTS WITH ADVANCED SMALL-CELL LUNG-CANCER, International journal of oncology, 6(2), 1995, pp. 425-429
CHEMOTHERAPY IN NON-SMALL-CELL LUNG-CANCER - A METAANALYSIS USING UPDATED DATA ON INDIVIDUAL PATIENTS FROM 52 RANDOMIZED CLINICAL-TRIALS
Authors: ALBERTI W ANDERSON G BARTOLUCCI A BELL D VILLALBA JB BRODIN O CARDIELLO C CARTEI F CARTEI G CELLERINO R CHASTANG C CORMIER Y COX JD CRINO L CROWLEY J DAUTZENBERG B DEPIERRE A DIETEMANN A DILLMAN RO DOI O FELD R FIGLIN R GANZ PA GREEN MR GREGOR A HELLE PA HERNDON JE HITOMI S HOST H IMAIZUMI M JETT JR JOHNSON D KAASA S KIMURA H KLASTERSKY J KONDO H KREISMAN H KRIS MG KUNISHIMA K KUWAHARA O LAD TE LAING AH MACBETH F MASAOKA A MATTSON K MINATEL E MIRA JG MORI T MOUNTAIN CF NIEDERLE N NIIRANEN A NOU E PAGE W PATER J PIANTADOSI S PISTERS KMW PYRHONEN S QUOIX E RAPP E ROWELL NP SAHMOUD T SAWAMURA K SCHALLIER DCC SCOTT C SIMPSON J STAGG M TERAMATSU T TROVO MG TSUCHIYA R TUMMARELLO D VANHOUTTE P VANZANDWIJK N VINCENT RG WADA H WHITE JE WILLIAMS CJ WOODS RL YAMAGUCHI Y ARRIAGADA R CARTMELLDAVIES J GIRLING DJ LECHEVALIER T MARSONI S PARMAR MKB PIGNON JP REKACEWICZ C SOUHAMI RL STEWART LA TARAYRE M TINAZZI A TONI V
Citation: W. Alberti et al., CHEMOTHERAPY IN NON-SMALL-CELL LUNG-CANCER - A METAANALYSIS USING UPDATED DATA ON INDIVIDUAL PATIENTS FROM 52 RANDOMIZED CLINICAL-TRIALS, BMJ. British medical journal, 311(7010), 1995, pp. 899-909
MAINTENANCE CHEMOTHERAPY IN PATIENTS WITH SMALL-CELL LUNG-CANCER AFTER INDUCTION CHEMOTHERAPY WITH IFOSFAMIDE, ETOPOSIDE AND ANTHRACYCLIN -RANDOMIZED TRIAL CONDUCTED BY THE EUROPEAN LUNG-CANCER WORKING PARTY
Authors: SCULIER JP BUREAU G GINER V THIRIAUX J MOMMEN P PAESMANS M KLASTERSKY J
Citation: Jp. Sculier et al., MAINTENANCE CHEMOTHERAPY IN PATIENTS WITH SMALL-CELL LUNG-CANCER AFTER INDUCTION CHEMOTHERAPY WITH IFOSFAMIDE, ETOPOSIDE AND ANTHRACYCLIN -RANDOMIZED TRIAL CONDUCTED BY THE EUROPEAN LUNG-CANCER WORKING PARTY, European journal of cancer, 31A, 1995, pp. 81-81
DELIVERED DOSE INTENSITY WITH AN INDUCTION CHEMOTHERAPY (CT) BY IFOSFAMIDE, ETOPOSIDE AND ANTHRACYCLIN FOR PATIENTS (PTS) WITH SMALL-CELL LUNG-CANCER (SCLC) - A REPORT BY THE EUROPEAN LUNG-CANCER WORKING PARTY
Authors: PAESMANS M SCULIER JP BUREAU G GINER V THIRIAUX J MOMMEN P KLASTERSKY J
Citation: M. Paesmans et al., DELIVERED DOSE INTENSITY WITH AN INDUCTION CHEMOTHERAPY (CT) BY IFOSFAMIDE, ETOPOSIDE AND ANTHRACYCLIN FOR PATIENTS (PTS) WITH SMALL-CELL LUNG-CANCER (SCLC) - A REPORT BY THE EUROPEAN LUNG-CANCER WORKING PARTY, European journal of cancer, 31A, 1995, pp. 91-91
PREVENTION AND THERAPY OF FUNGAL-INFECTIONS IN CANCER-PATIENTS - A REVIEW OF RECENTLY PUBLISHED INFORMATION
Authors: KLASTERSKY J
Citation: J. Klastersky, PREVENTION AND THERAPY OF FUNGAL-INFECTIONS IN CANCER-PATIENTS - A REVIEW OF RECENTLY PUBLISHED INFORMATION, Supportive care in cancer, 3(6), 1995, pp. 393-401
PACLITAXEL-INDUCED CUTANEOUS TOXICITY
Authors: BERGHMANS T KLASTERSKY J
Citation: T. Berghmans et J. Klastersky, PACLITAXEL-INDUCED CUTANEOUS TOXICITY, Supportive care in cancer, 3(3), 1995, pp. 203-204
Risultati: 1-25 | 26-50 | 51-58